DOCSLIB.ORG

Таблица 1. Противомикробные И Антисептические Препараты, Применяемые В Гинекологии G Genito Urinary System and Sex Hormones

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Таблица 1. Противомикробные И Антисептические Препараты, Применяемые В Гинекологии G Genito Urinary System and Sex Hormones Таблица 1. Противомикробные и антисептические препараты, применяемые в гинекологии G GENITO URINARY SYSTEM AND SEX HORMONES G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS G01AA ANtibiotics G01AB ArseNic compouNds G01AC QuiNoliNe derivatives G01AD OrgaNic acids G01AE SulfoNamides G01AF Imidazole derivatives G01AG Triazole derivatives G01AX Other aNtiiNfectives aNd aNtiseptics G01AAANtibiotics G01AA01 NystatiN G01AA02 NatamyciN (натамицин: суппозитории вагинальные) G01AA03 amphotericiN B G01AA04 caNdicidiN G01AA05 chlorampheNicol G01AA06 hachimyciN G01AA07 oxytetracycliNe G01AA08 carfecilliN G01AA09 mepartriciN G01AA10 cliNdamyciN G01AA11 peNtamyciN G01AA51 NystatiN, combiNatioNs G01AB ArseNic compouNds G01AB01 acetarsol G01AC QuiNoliNe derivatives G01AC01 diiodohydroxyquiNoliNe G01AC02 clioquiNol G01AC03 chlorquiNaldol G01AC05 dequaliNium G01AC06 broxyquiNoliNe G01AC30 oxyquiNoliNe G01AD OrgaNic acids G01AD01lactic acid G01AD02 acetic acid G01AD03 ascorbic acid G01AE SulfoNamides G01AE01 sulfatolamide G01AE10 combiNatioNs of sulfoNamides G01AF Imidazole derivatives G01AF01 metroNidazole G01AF02 clotrimazole (клотримазол: гель вагинальный, суппозитории вагинальные, таблетки вагинальные) G01AF04 micoNazole G01AF05 ecoNazole G01AF06 orNidazole G01AF07 isocoNazole G01AF08 tiocoNazole G01AF11 ketocoNazole G01AF12 feNticoNazole G01AF13 azaNidazole G01AF14 propeNidazole G01AF15 butocoNazole G01AF16 omocoNazole G01AF17 oxicoNazole G01AF18 flutrimazole G01AF20 combiNatioNs of imidazole derivatives G01AG Triazole derivatives G01AG02 tercoNazole G01AX Other aNtiiNfectives aNd aNtiseptics G01AX01 clodaNtoiN G01AX02 iNosiNe G01AX03 policresuleN G01AX05 Nifuratel G01AX06 furazolidoNe G01AX09 methylrosaNiliNe G01AX11 povidoNe-iodiNe G01AX12 ciclopirox G01AX13 protiofate G01AX14 lactobacillus fermeNtum G01AX15 copper usNate G01AX66 octeNidiNe, combiNatioNs G GENITO URINARY SYSTEM AND SEX HORMONES G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS G01B ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS G01BA ANtibiotics aNd corticosteroids G01BC QuiNoliNe derivatives aNd corticosteroids G01BD ANtiseptics aNd corticosteroids G01BE SulfoNamides aNd corticosteroids G01BF Imidazole derivatives aNd corticosteroids D DERMATOLOGICALS D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AA TetracycliNe aNd derivatives D06AX Other aNtibiotics for topical use D06B CHEMOTHERAPEUTICS FOR TOPICAL USE D06BA SulfoNamides D06BB ANtivirals D06BX Other chemotherapeutics D06C ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS D06AA TetracycliNe aNd derivatives D06AA01 demeclocycliNe D06AA02 chlortetracycliNe D06AA03 oxytetracycliNe D06AA04 tetracycliNe D06AX Other aNtibiotics for topical use D06AX01 fusidic acid D06AX02 chlorampheNicol D06AX04 NeomyciN D06AX05 bacitraciN D06AX07 geNtamiciN D06AX08 tyrothriciN D06AX09 mupirociN D06AX10 virgiNiamyciN D06AX11 rifaximiN D06AX12 amikaciN D06AX13 retapamuliN D06BA SulfoNamides D06BA01 silver sulfadiaziNe D06BA02 sulfathiazole D06BA03 mafeNide D06BA04 sulfamethizole D06BA05 sulfaNilamide D06BA06 sulfameraziNe D06BA51 silver sulfadiaziNe, combiNatioNs D06BB ANtivirals D06BB01 idoxuridiNe D06BB02 tromaNtadiNe D06BB03 aciclovir D06BB04 podophyllotoxiN D06BB05 iNosiNe D06BB06 peNciclovir D06BB07 lysozyme D06BB08 ibacitabiNe D06BB09 edoxudiNe D06BB10 imiquimod D06BB11 docosaNol D06BB12 siNecatechiNs D06BB53 aciclovir, combiNatioNs D06BX Other chemotherapeutics D06BX01 metroNidazole D06BX02 iNgeNolmebutate D06C ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS Диоксометилтетрагидропиримидин + сульфадиметоксин + тримекаин + хлорамфеникол: мазь для наружного применения P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS P01 ANTIPROTOZOALS P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES P01AB Nitroimidazole derivatives P01AB01 metroNidazole (метронидазол: раствор для внутривенного введения; раствор для инфузий; таблетки; таблетки, покрытые оболочкой; таблетки, покрытые пленочной оболочкой) P01AB02 tiNidazole P01AB03 orNidazole P01AB04 azaNidazole P01AB05 propeNidazole P01AB06 Nimorazole P01AB07 secNidazole J ANTIINFECTIVES FOR SYSTEMIC USE J01 ANTIBACTERIALS FOR SYSTEMIC USE J02 ANTIMYCOTICS FOR SYSTEMIC USE J04 ANTIMYCOBACTERIALS J05 ANTIVIRALS FOR SYSTEMIC USE J06 IMMUNE SERA AND IMMUNOGLOBULINS J07 VACCINES Красным шрифтом выделены ЛС, включенные в перечень ЖНВЛП 2012—2013 гг. Таблица 2. Воспалительные болезни женских тазовых органов (по МКБ-Х) N70-N77. Воспалительные болезни женских тазовых органов N70. Сальпингит и N70.0. Острый сальпингит и оофорит; оофорит N70.1. Хронический сальпингит и оофорит; N70.9. Сальпингит и оофорит неуточненные N71. Воспалительная N71.0. Острая воспалительная болезнь матки; болезнь матки, кроме N71.1. Хроническая воспалительная болезнь матки; шейки матки (в т. ч. N71.9. Воспалительная болезнь матки неуточненная эндометрит, миометрит) N72. Воспалительная болезнь шейки матки (в т. ч. цервицит, эндоцервицит, экзоцервицит) N73. Другие N73.0. Острый параметрит и тазовый целлюлит; воспалительные болезни N73.1. Хронический параметрит и тазовый целлюлит; женских тазовых органов N73.2. Параметрит и тазовый целлюлит неуточненные; N73.3. Острый тазовый перитонит у женщин; N73.4. Хронический тазовый перитонит у женщин; N73.5. Тазовый перитонит у женщин неуточненный; N73.6. Тазовые перитонеальные спайки у женщин; N73.8. Другие уточненные воспалительные болезни женских тазовых органов; N73.9. Воспалительные болезни женских тазовых органов неуточненные N74.* Воспалительные N74.0.* Туберкулезная инфекция шейки матки (А18.1); болезни женских тазовых N74.1.* Воспалительные болезни женских тазовых органов при болезнях, органов туберкулезной этиологии (А18.1); классифицированных в N74.2.* Воспалительные болезни женских тазовых других рубриках органов, вызванные сифилисом (А51.4, А52.7); N74.3.* Гонококковые воспалительные болезни женских тазовых органов (А54); N74.4.* Воспалительные болезни женских тазовых органов, вызванные хламидиями (А56.1); N74.8.* Воспалительные болезни женских тазовых органов при других болезнях, классифицированных в других рубриках N75. Болезни N75.0. Киста бартолиновой железы; бартолиновой железы N75.1. Абсцесс бартолиновой железы; N75.8. Другие болезни бартолиновой железы; N75.9. Болезнь бартолиновой железы неуточненная N76. Другие N76.0. Острый вагинит; воспалительные болезни N76.1. Подострый и хронический вагинит; влагалища и вульвы N76.2. Острый вульвит; N76.3. Подострый и хронический вульвит; N76.4. Абсцесс вульвы; N76.5. Изъязвление влагалища N76.6. Изъязвление вульвы N76.8. Другие уточненные воспалительные болезни влагалища и вульвы N77.* Изъязвление и N77.0.* Изъязвление вульвы при инфекционных и воспаление вульвы и паразитарных болезнях, классифицированных в других влагалища при болезнях, рубриках классифицированных в N77.1.* Вагинит, вульвит и вульвовагинит при других рубриках инфекционных и паразитарных болезнях, классифицированных в других рубриках N77.8.* Изъязвление и воспаление вульвы и влагалища при болезнях, классифицированных в других рубриках Таблица 3. Стандарт первичной медико-санитарной помощи женщинам при воспалительных заболеваниях половых органов (3) Перечень лекарственных препаратов для медицинского применения при воспалительных заболеваниях половых органов (зарегистрированных на территории Российской Федерации, с указанием средних суточных и курсовых доз) Код по МКБ-Х* Нозологические единицы N70.0. Острый сальпингит и оофорит N70.1. Хронический сальпингит и оофорит N70.9. Сальпингит и оофорит неуточненные N71.0. Острая воспалительная болезнь матки N71.1. Хроническая воспалительная болезнь матки N71.9. Воспалительная болезнь матки неуточненная N73.1. Хронический параметрит и тазовый целлюлит N73.6. Тазовые перитонеальные спайки у женщин N73.8. Другие уточненные воспалительные болезни женских тазовых органов N73.9. Воспалительные болезни женских тазовых органов неуточненные N74.3. Гонококковые воспалительные болезни женских тазовых органов (A54.2+) N74.4. Воспалительные болезни женских тазовых органов, вызванные хламидиями (A56.1+) Код Анатомо- Наименование Усреднен Единиц ССД* СКД* терапевтическо лекарственного ный ы ** *** -химическая препарата** показате измерен классификация ль ия частоты предоста вления J01AA Тетрациклины 0,4 Доксициклин мг 200 14 000 J01CR Комбинации 0,1 пенициллинов, включая комбинации с ингибиторами бета-лактамаз Амоксициллин + мг 3 600 36 000 [Клавулановая кислота] J01DD Цефалоспорины 0,5 3-го поколения Цефтазидим мг 4 000 28 000 Цефотаксим мг 4000 28 000 Цефтриаксон мг 2 000 14 000 J01FA Макролиды 0,5 Кларитромицин мг 1 000 7 000 Азитромицин мг 500 5 000 Джозамицин мг 2 000 14 000 J01FF Линкозамиды 0,5 Клиндамицин мг 900 9 000 J01GB Другие 0,2 аминогликозиды Амикацин мг 1 000 7 000 J01MA Фторхинолоны 0,6 Ципрофлоксацин мг 1 000 7 000 Левофлоксацин мг 500 5 000 J01XD Производные 0,8 имидазола Метронидазол мг 1 500 10 500 Метронидазол мл 300 900 J02AC Производные 0,3 триазола Флуконазол мг 50 150 L03AB Интерфероны 0,7 Интерферон альфа МЕ 1 000 10 000 M01AB Производные 0,15 уксусной кислоты и родственные соединения Диклофенак мг 75 225 Кеторолак мг 10 30 M01AE Производные 0,05 пропионовой кислоты Кетопрофен мг 100 300 * Международная статистическая классификация болезней и проблем, связанных со здоровьем, Х пересмотра. ** Международное непатентованное или химическое наименование лекарственного препарата, а в случаях их отсутствия -- торговое наименование лекарственного препарата. *** Средняя суточная
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Safety, Tolerability and Pharmacokinetics of Intravaginal Pentamycin
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by edoc Pharmacology Chemotherapy 2010;56:190–196 Received: March 20, 2009 DOI: 10.1159/000316329 Accepted after revision: January 12, 2010 Published online: June 10, 2010 Safety, Tolerability and Pharmacokinetics of Intravaginal Pentamycin a a c b B. Frey Tirri J. Bitzer B. Geudelin J. Drewe a b Departments of Obstetrics and Gynecology, and Clinical Pharmacology, University Hospital Basel, and c Mediante GmbH, Basel , Switzerland Key Words cin does not cause adverse reactions compared with vehicle -Antimicrobial agents ؒ Pentamycin ؒ Pharmacokinetics ؒ and is not absorbed through the intact or the inflamed va Polyene antifungal antibiotic ؒ Vaginal infections gina. Copyright © 2010 S. Karger AG, Basel Abstract Background/Aims: Intravaginal pentamycin is a polyene Introduction macrolide with a broad spectrum of antimicrobial activity and is effective in various forms of infectious vaginitis. We The most common vaginal disorders include vaginal evaluated the safety, tolerability and pharmacokinetics of candidiasis, vaginal trichomoniasis and bacterial vagino- escalating doses of this product. Methods: Nineteen healthy sis [1–5] . Forms of infectious vaginitis sustained by mixed volunteers were randomized to receive double blind one of micro-organisms are also observed frequently [6] . Vagi- five doses of intravaginal pentamycin (3, 10, 30, 60 or 100 mg) nal infections can be successfully treated by using one or or the corresponding dose of pentamycin vehicle daily for more pathogen-specific antimicrobials [1, 3, 7–9] , but, be- 6 days. Patients with symptomatic vaginitis received a single fore vaginitis is treated, the cause must be ascertained by dose of 60 (n = 6) or 100 mg (n = 6) of intravaginal penta- using appropriate laboratory tests [1, 2, 6, 7, 10] .
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • United States Patent 19 [11] 3,957,754 Aszalos Et Al
    United States Patent 19 [11] 3,957,754 ASzalos et al. (45) May 18, 1976 54 COMPLEXES OF ANTIFUNGAL POLYENE 3,777,018 12/1973 Gordon et al................ 260/210 AB ANTIBOTCS FOREIGN PATENTS OR APPLICATIONS (75) Inventors: Adorjan Aszalos, Princeton; John Vandeputte, Milltown, both of N.J. 795,482 5/1958 United Kingdom.......... 260/210 AB (73) Assignee: E. R. Squibb & Sons, Inc., OTHER PUBLICATIONS Princeton, N.J. 22 Filed: Jan. 13, 1975 Mazor et al. “Chem. Abst." Vol. 57, 1962, p. 956g. 21 Appl. No.: 540,750 Primary Examiner-Johnnie R. Brown Related U.S. Application Data Attorney, Agent, or Firm-Lawrence S. Levinson; 62 Division of Ser. No. 100,492, Dec. 21, 1970, Pat. No. Merle J. Smith; Stephen B. Davis 3,879,374. 52 U.S. Cl........................... 260/210 AB; 424/180; 57) ABSTRACT 424/181 51 int. Cl'.......................................... C07H 15/20 Disclosed herein are complexes of polyene antibiotics 58 Field of Search.............. 260/210 AB; 424/117, which are soluble in alcohol or in water and alcohol. 424/119 These complexes are prepared in alcoholic solutions and have been found to be useful as antifungal agents 56) References Cited which can be orally administered. UNITED STATES PATENTS 6 Claims, No Drawings 2,865,807 12, 1958 Dutcher et al............... 260/20 AB 3,957,754 2 Alcohols that can be utilized to carry out the reaction COMPLEXES OF ANTIFUNGAL POLYENE are the lower alkyl alcohols of from 1 to 6 carbons such ANTBIOTICS as methanol, ethanol, isopropanol, isobutanol, butanol, This is a division of Ser.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Oxiconazole Nitrate (BANM, USAN, Rinnm) Tral.: Kenacomb; Otocomb Otic; Austria: Mycostatin V; Mycostatin- Fungichromin; Lagosin; Pentamicina
    544 Antifungals Port.: Mycostatin; S.Afr.: Candacide; Canstat; Mycostatin; Nystacid; Singa- Preparations Profile pore: Mycostatin†; Spain: Mycostatin; Swed.: Mycostatin; Switz.: Mycos- Parconazole is an antifungal that has been used as the hydrochlo- tatine; Thai.: Lystin†; Mycostatin; Turk.: Fungostatin; Mikostatin; UAE: Proprietary Preparations (details are given in Part 3) ride in the treatment of gastrointestinal candidiasis in veterinary Mikostat; UK: Nystamont†; Nystan; USA: Mycostatin; Nilstat; Nystop; Pedi- Dri; Venez.: Micostatin; Nistafesa†; Romalina†. Austria: Afongan; Fr.: Fongamil; Fongarex; Gr.: Fongamil; Hung.: Mikogal; medicine. Mex.: Afongan; Port.: Afongan†; Fongamil; Rus.: Mikogal (Микогал). Multi-ingredient: Arg.: Bacticort Complex; Bexon; Biotaer Gamma†; Bi- otaer Nebulizable; Dermadex NN; Farm-X Duo; Fasigyn Nistatina; Flagys- tatin; Kenacomb; Linfol; Min O; Naxo TV; Neocolpoben†; Nistinol; O-Biol; Pentamycin O-Biol P; Pelvicillin NF; Polygynax; Terra-Cortril Nistatina†; Tratomax; Aus- Oxiconazole Nitrate (BANM, USAN, rINNM) tral.: Kenacomb; Otocomb Otic; Austria: Mycostatin V; Mycostatin- Fungichromin; Lagosin; Pentamicina. Zinkoxid; Topsym polyvalent; Belg.: Eoline†; Mycolog; Polygynax†; Braz.: Nitrato de oxiconazol; Oxiconazole, Nitrate d’; Oxiconazoli Ni- Benzevit; Bio-Vagin; Colpagex N; Colpatrin; Colpist; Colpistar; Colpistatin; Пентамицин tras; Ro-13-8996; Ro-13-8996/001; Ro-13-8996/000 (oxicona- Colpolase; Dermodex; Dermokin; Donnagel; Flagyl Nistatina; Fungimax; Gi- C35H58O12 = 670.8. nec†; Ginestatin; Gynax-N; Londerm-N; Minegyl C/Nistatina†; Mud; Nax- zole); SGD-301-76; ST-813. 2′,4′-Dichloro-2-imidazol-1-ylace- CAS — 6834-98-6. ogin Composto; Neolon-D; Nistazol†; Omcilon A M; Onciplus; Oxyderme; tophenone (Z)-O-(2,4-dichlorobenzyl)oxime mononitrate. Poliginax; Tricolpex; Tricomax; Trivagel N; Vagi Biotic; Vagimax; Vagitrin-N; ATC — G01AA11. Canad.: Flagystatin; Kenacomb†; ratio-Triacomb; Triacomb†; Viaderm-KC; Оксиконазола Нитрат ATC Vet — QG01AA11.
    [Show full text]
  • B DÉCISION DE LA COMMISSION Du 8 Mai 1996 Portant
    1996D0335 — FR — 09.02.2006 — 001.001 — 1 Ce document constitue un outil de documentation et n'engage pas la responsabilité des institutions ºB DÉCISION DE LA COMMISSION du 8 mai 1996 portant établissement d'un inventaire et d'une nomenclature commune des ingrédients employés dans les produits cosmétiques (Texte présentant de l'intérêt pour l'EEE) (96/335/CE) (JO L 132 du 1.6.1996, p. 1) Modifiée par: Journal officiel no page date ºM1 Décision de la Commission 2006/257/CE, du 9 février 2006 L 97 1 5.4.2006 1996D0335 — FR — 09.02.2006 — 001.001 — 2 ¼B DÉCISION DE LA COMMISSION du 8 mai 1996 portant établissement d'un inventaire et d'une nomenclature commune des ingrédients employés dans les produits cosmétiques (Texte présentant de l'intérêt pour l'EEE) (96/335/CE) LA COMMISSION DES COMMUNAUTÉS EUROPÉENNES, vu le traité instituant la Communauté européenne, vu la directive 76/768/CEE du Conseil, du 27 juillet 1976, concernant le rapprochement des législations des États membres relatives aux produits cosmétiques (1), modifiée en dernier lieu par la directive 95/34/CE de la Commission (2), et notamment son article 5 bis et son article 7 para- graphe 2, après consultation du comité scientifique de cosmétologie, considérant que l'inventaire des ingrédients employés dans les produits cosmétiques doit comprendre une partie relative aux matières premières parfumantes et aromatiques et une autre relative aux autres substances; considérant que cet inventaire doit contenir des informations sur l'iden- tité de chaque ingrédient, à savoir notamment les dénominations chimi- ques, INCI (ex-CTFA), Ph.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,504,381 B2 Mor Et Al
    USOO7504381 B2 (12) United States Patent (10) Patent No.: US 7,504,381 B2 Mor et al. (45) Date of Patent: Mar. 17, 2009 (54) ANTIMICROBIAL AGENTS Tossi et al. "Amphipathic, Alpha-Helical Antimicrobial Peptides'. Biopolymers, 55(1): 4-30, 2000. Abstract, Table 1, p. 7-8, Table II, p. (75) Inventors: Amram Mor, Haifa (IL); Inna 13. Radzishevsky, Haifa (IL) Huang "Peptide-Lipid Interactions and Mechanisms of Antimicro bial Peptides”, Novartis Found Symposium, 225: 188-200, 1999. (73) Assignee: Technion Research & Development Discussion 200-206. Epand et al. “Mechanisms for the Modulation of Membrane Bilayer Foundation Ltd., Haifa (IL) Properties by Amphipathic Helical Peptides'. Biopolymers, 37(5): 319-338, 1995. Abstract. (*) Notice: Subject to any disclaimer, the term of this Ono et al. “Design and Synthesis of Basic Peptides Having patent is extended or adjusted under 35 Amphipathic Beta-Structure and Their Interaction With U.S.C. 154(b) by 153 days. Phospholipid Membranes'. Biochimica et Biophysica Acta (BBA) Biomembranes, 1022(2): 237-244, 1990. Abstract. (21) Appl. No.: 11/234,183 Aarbiou et al. “Human Neutrophil Defensins Induce Lung Epithelial Cell Proliferation. In Vitro”, Journal of Leukocyte Biology, 72: 167 (22) Filed: Sep. 26, 2005 174, 2002. Acar “Consequences of Bacterial Resistance to Antibiotics in Medi (65) Prior Publication Data cal Practice'. Clinical Infectious Diseases, 24(Suppl. 1): S17-S18. 1997. US 2006/OO74O21 A1 Apr. 6, 2006 Alan et al. “Expression of A Magainin-Type Antimicrobial Peptide Gene (MSI-99) in Tomato Enhances Resistance to Bacterial Speck Related U.S. Application Data Disease'. Plant Cell Reports, 22:388-396, 2004.
    [Show full text]
  • Diccionario Del Sistema De Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS
    DIRECCION GENERAL DE MEDICAMENTOS, INSUMOS Y DROGAS - DIGEMID EQUIPO DE ASESORIA - AREA DE CATALOGACION Diccionario del Sistema de Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS CODIGO DESCRIPCION ATC EN CASTELLANO DESCRIPCION ATC EN INGLES FUENTE A TRACTO ALIMENTARIO Y METABOLISMO ALIMENTARY TRACT AND METABOLISM ATC OMS A01 PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01A PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01AA Agentes para la profilaxis de las caries Caries prophylactic agents ATC OMS A01AA01 Fluoruro de sodio Sodium fluoride ATC OMS A01AA02 Monofluorfosfato de sodio Sodium monofluorophosphate ATC OMS A01AA03 Olaflur Olaflur ATC OMS A01AA04 Fluoruro de estaño Stannous fluoride ATC OMS A01AA30 Combinaciones Combinations ATC OMS A01AA51 Fluoruro de sodio, combinaciones Sodium fluoride, combinations ATC OMS A01AB Antiinfecciosos y antisépticos para el tratamiento oral local Antiinfectives and antiseptics for local oral treatment ATC OMS A01AB02 Peróxido de hidrógeno Hydrogen peroxide ATC OMS A01AB03 Clorhexidina Chlorhexidine ATC OMS A01AB04 Amfotericina B Amphotericin B ATC OMS A01AB05 Polinoxilina Polynoxylin ATC OMS A01AB06 Domifeno Domiphen ATC OMS A01AB07 Oxiquinolina Oxyquinoline ATC OMS A01AB08 Neomicina Neomycin ATC OMS A01AB09 Miconazol Miconazole ATC OMS A01AB10 Natamicina Natamycin ATC OMS A01AB11 Varios Various ATC OMS A01AB12 Hexetidina Hexetidine ATC OMS A01AB13 Tetraciclina Tetracycline ATC OMS A01AB14 Cloruro de benzoxonio
    [Show full text]